Access to Advanced Therapy Medicinal Products in the EU: Where Do We Stand?

in European Journal of Health Law
Restricted Access
Get Access to Full Text
Rent on DeepDyve

Have an Access Token?



Enter your access token to activate and access content online.

Please login and go to your personal user account to enter your access token.



Help

Have Institutional Access?



Access content through your institution. Any other coaching guidance?



Connect

Abstract

The European Union has a public health strategy and will generally ensure in all its policies and activities a “high level of human health protection”. The new Regulation (EC) no 1394/2007 on advanced therapy medicinal products (ATMP), stems from this global policy and aims to harmonise access to the ATMP market. A real will for the harmonisation is clearly expressed in legal texts and enforced in the implementable procedures and requirements. However, several barriers remain. On the one hand, the scope of the ATMP Regulation is limited. On the other hand, Member States benefit from a wide margin of action.

Access to Advanced Therapy Medicinal Products in the EU: Where Do We Stand?

in European Journal of Health Law

Sections

Information

Content Metrics

Content Metrics

All Time Past Year Past 30 Days
Abstract Views 6 6 5
Full Text Views 15 15 10
PDF Downloads 9 9 4
EPUB Downloads 0 0 0